<DOC>
	<DOCNO>NCT02623621</DOCNO>
	<brief_summary>A grow amount report consistently evidence sustain inhibition angiogenesis effective therapeutic strategy , able improve outcome metastatic colorectal cancer ( mCRC ) patient . In last decade different biologic agent target angiogenesis approve treatment mCRC , bevacizumab , aflibercept regorafenib , , recently , solid evidence demonstrate efficacy sustain antiangiogenic approach even beyond first progression bevacizumab-containing regimen . In particular , two phase III randomize trial prove effectiveness prosecute bevacizumab second-line switching chemotherapeutic regimen patient already treat bevacizumab first-line . Preliminary experience evidence circulate level angiogenesis-related marker significantly modulate first-line chemotherapy plus bevacizumab . In particular , wide variability plasma soluble Vascular Endothelial Growth Factor Receptor-2 ( VEGFR-2 ) level observe time disease progression retrospective data suggest benefit continuation bevacizumab may restrict patient high level soluble VEGFR-2 first evidence disease progression . This study aim prospectively validate retrospective data .</brief_summary>
	<brief_title>Soluble Vascular Endothelial Growth Factor Receptor 2 Predictor Benefit From Bevacizumab Beyond Progression Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Male female â‰¥ 18 year age Progressive disease firstline chemotherapy plus bevacizumab , include fluoropyrimidine alone ( 5fluorouracil capecitabine ) , fluoropyrimidine combination oxaliplatin ( XELOX FOLFOX regimen ) irinotecan ( FOLFIRI regimen ) oxaliplatin irinotecan ( FOLFOXIRI regimen ) ; No 3 month last administration bevacizumab evidence progressive disease allow ; Measurable disease accord RECIST 1.1 . Indication secondline treatment bevacizumabcontaining secondline regimen ( secondline XELOX , FOLFOX , FOLFIRI FOLFOXIRI plus bevacizumab allow ) ; Neutrophils 1.5 x 109/L , Platelets 100 x 109/L , Hgb &gt; 9 g/dl Total bilirubin 1.5 time uppernormal limit ( UNL ) institutional normal value ASAT ( SGOT ) and/or ALAT ( SGPT ) 2.5 x UNL , 5 x UNL case liver metastasis , alkaline phosphatase 2.5 x UNL , 5 x UNL case liver metastasis Creatinine clearance &gt; 50 mL/min serum creatinine 1.5 x UNL Urine dipstick proteinuria &lt; 2+ . Patients discover 2+ proteinuria dipstick urinalysis baseline , undergo 24hour urine collection must demonstrate &lt; 1 g protein/24 hr Will ability comply protocol Written inform consent study procedure . Patient unable give consent Absolute contraindication use bevacizumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>